Detailed Guide Coming Soon
We're working on a comprehensive educational guide for the Semaglutide Dose Calculator. Check back soon for step-by-step explanations, formulas, real-world examples, and expert tips.
The Semaglutide Dose Escalation Calculator models the FDA-approved dose titration schedule for semaglutide, which is available as Wegovy (for chronic weight management at doses up to 2.4 mg weekly) and Ozempic (for type 2 diabetes at doses up to 2.0 mg weekly). Semaglutide requires a gradual dose escalation over 16 to 20 weeks to minimize gastrointestinal side effects, and this calculator tracks the patient's current position in the titration schedule, identifies the correct pen device for each dose level, and projects when the target maintenance dose will be reached. The dose escalation protocol exists because semaglutide causes significant gastrointestinal side effects, particularly nausea, vomiting, and diarrhea, when initiated at full therapeutic doses. By starting at 0.25 mg weekly and increasing every 4 weeks, the body gradually adapts to the GLP-1 receptor stimulation, reducing the incidence and severity of side effects. In the STEP 1 trial, approximately 44 percent of patients on semaglutide 2.4 mg reported nausea at some point during treatment, but the slow titration schedule helped most patients manage through these early side effects without discontinuing. The Wegovy dose escalation follows five steps: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1.0 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and 2.4 mg from week 17 onward as the maintenance dose. Each dose level requires a different pen device with a distinct color label. Ozempic follows a similar but compressed schedule: 0.25 mg for weeks 1 to 4, 0.5 mg from week 5 onward (initial maintenance), with optional increases to 1.0 mg and then 2.0 mg based on glycemic response. Understanding which pen to use and when to advance is essential for safe and effective therapy. This calculator is used by patients who need to track their position in the titration schedule, by physicians and nurse practitioners who are prescribing semaglutide for the first time and want to confirm the correct dose advancement timeline, by pharmacists who need to verify that the correct pen device is being dispensed for the patient's current titration phase, and by prior authorization teams who need to confirm that the dose matches the approved escalation schedule before authorizing refills.
Weekly Dose at Week W = Titration Schedule Lookup(W), where the Wegovy schedule is: Weeks 1-4 = 0.25 mg, Weeks 5-8 = 0.5 mg, Weeks 9-12 = 1.0 mg, Weeks 13-16 = 1.7 mg, Weeks 17+ = 2.4 mg (maintenance). Monthly medication cost at each step varies by pen. For a worked example: a patient at Week 10 is on the 1.0 mg dose (Step 3 of 5), has been on semaglutide for 70 days, and should be using the Wegovy 1.0 mg pen (yellow label). They will advance to 1.7 mg at Week 13 and reach the maintenance dose of 2.4 mg at Week 17, approximately 49 days from their current position.
- 1Select the semaglutide brand and indication. Wegovy is prescribed for chronic weight management and follows a 5-step titration to 2.4 mg. Ozempic is prescribed for type 2 diabetes and follows a 3 to 4-step titration to 1.0 mg or 2.0 mg. The dose schedules differ between these brands, and the calculator adjusts the titration timeline and pen device assignments accordingly. Patients switching between brands (for example, from Ozempic to Wegovy due to insurance changes) can enter their current dose to determine where they fall in the new brand's titration schedule.
- 2Enter the date you started semaglutide therapy or your current week number. The calculator uses this to determine your exact position in the titration schedule. If you are restarting after a gap in treatment, the calculator applies the FDA-recommended guidance: if you missed 2 or fewer consecutive weekly doses, resume at the same dose; if you missed more than 2 weeks, consider restarting at a lower dose to re-acclimate and reduce the risk of gastrointestinal side effects upon resumption.
- 3The calculator displays your current prescribed dose, the corresponding pen device (identified by dose strength and label color), and the injection volume. Wegovy pens are pre-filled single-dose devices, while Ozempic pens are multi-dose devices that deliver multiple injections per pen. Understanding the pen mechanics is important because Ozempic pens are dialed to different dose markings depending on the titration phase, while Wegovy pens are fixed-dose and require a new pen type at each escalation step.
- 4Review the complete titration timeline showing all dose escalation steps, the date of each planned dose increase, and the expected time to reach your target maintenance dose. The calculator accounts for the 4-week intervals between dose increases and highlights any upcoming transitions. For patients experiencing significant side effects at their current dose, the calculator can model extended titration (staying at a dose for 8 weeks instead of 4) and show how this affects the timeline to maintenance.
- 5The calculator provides pen supply management information showing how many pens you need at each dose level, when to request refills, and typical insurance authorization timelines for dose transitions. Since each Wegovy dose level requires a different pen device with a unique NDC (National Drug Code), your pharmacy needs to order the correct pen for each transition. Planning ahead by 1 to 2 weeks prevents gaps in treatment due to pharmacy stocking delays or prior authorization requirements for the new dose level.
- 6For patients experiencing dose-limiting side effects, the calculator includes a tolerability management module. Common strategies include extending the duration at the current dose (spending 8 weeks instead of 4 at a dose level before escalating), taking the injection in the evening instead of the morning to sleep through peak nausea, eating smaller meals on injection day, and using anti-nausea medications like ondansetron during the first 2 to 3 days after each injection. The calculator adjusts the projected timeline based on any dose delays entered.
- 7The output includes a printable dose escalation card that patients can share with their pharmacy and healthcare provider, ensuring everyone involved in their care is aligned on the current and upcoming dose schedule. This is particularly valuable for patients managing their titration across multiple providers or during transitions between healthcare systems.
This patient is in the second phase of the Wegovy titration, having completed the initial 0.25 mg phase. They are using the 0.5 mg Wegovy pen. They will advance through three more dose levels over the next 11 weeks before reaching the maintenance dose of 2.4 mg.
Ozempic has a simpler titration: 0.25 mg for 4 weeks then 0.5 mg as the initial maintenance dose. Unlike Wegovy, further escalation to 1.0 mg and 2.0 mg is optional and based on glycemic response rather than following a fixed schedule. The physician will assess A1C at 3 months to determine if dose escalation is warranted.
This patient experienced significant nausea at the 1.0 mg dose and their physician extended the time at this level from 4 to 8 weeks. This is a common and recommended strategy that delays reaching the maintenance dose by 4 weeks but significantly improves tolerability and reduces the risk of treatment discontinuation.
After a gap of more than 2 weeks, restarting at the previous dose carries a higher risk of severe nausea and vomiting. Stepping back by one dose level allows the body to re-acclimate. This patient will reach their maintenance dose 8 weeks after restarting rather than the 4 weeks it would take if they resumed at 1.7 mg directly.
Obesity medicine clinics use the dose escalation calculator as part of their patient onboarding workflow. When a new patient starts Wegovy, the clinic generates a personalized titration timeline showing every dose change date, the corresponding pen device, and scheduled follow-up appointments aligned with dose transitions. This proactive planning reduces confusion, ensures patients have the correct pen at each transition, and improves adherence during the critical first 4 months of treatment.
Pharmacists use dose escalation tracking to verify that prescription refills align with the expected titration schedule. When a patient requests a Wegovy 1.7 mg pen refill at week 8 (when they should still be on 1.0 mg), the pharmacist can identify the discrepancy and contact the prescriber. This verification catches prescribing errors and insurance fraud, and ensures patients are titrating safely according to the FDA-approved schedule.
Insurance prior authorization teams use the dose escalation timeline to validate claims during dose transitions. Some plans require a new prior authorization at each dose level, particularly for Wegovy, because each pen is a separate NDC code. Understanding the expected transition dates allows prior auth teams to proactively initiate the approval process before the patient needs to advance, preventing treatment interruptions caused by administrative delays.
Clinical research coordinators use standardized dose escalation calculators to ensure protocol compliance in GLP-1 clinical trials. Deviations from the prescribed titration schedule can compromise trial data and may require protocol deviation documentation. By automating dose tracking across hundreds of trial participants, research sites minimize protocol deviations related to incorrect dose timing.
Patients switching from Ozempic to Wegovy (often due to wanting the higher 2.4
Patients switching from Ozempic to Wegovy (often due to wanting the higher 2.4 mg dose for weight management) do not need to restart the titration from the beginning. A patient currently stable on Ozempic 1.0 mg can transition directly to Wegovy 1.7 mg (the next step up) and then escalate to 2.4 mg after 4 weeks. This transition pathway avoids unnecessary re-titration through doses the patient has already tolerated while respecting the escalation principle for the new, higher doses.
Patients with renal impairment (eGFR below 30 mL/min) represent a special case
Patients with renal impairment (eGFR below 30 mL/min) represent a special case because semaglutide is primarily eliminated through proteolytic degradation rather than renal excretion. No dose adjustment is required for renal impairment per the FDA label, but these patients may be more susceptible to dehydration from gastrointestinal side effects, which can worsen renal function. The calculator flags renal impairment as a monitoring consideration and recommends closer hydration monitoring during dose escalation.
Elderly patients (over age 75) are underrepresented in clinical trials and may
Elderly patients (over age 75) are underrepresented in clinical trials and may require a more conservative titration approach. While no formal dose adjustment is recommended, elderly patients are more vulnerable to dehydration from nausea and vomiting, have higher baseline fall risk that could be exacerbated by rapid weight loss, and may have reduced appetite at baseline. Some geriatric specialists recommend 8-week intervals between dose increases instead of 4 weeks for patients over 75.
| Week | Wegovy Dose | Wegovy Pen Color | Ozempic Dose | Ozempic Pen |
|---|---|---|---|---|
| 1-4 | 0.25 mg | Dark gray | 0.25 mg | 0.25/0.5 mg pen (red label) |
| 5-8 | 0.5 mg | Dark red | 0.5 mg (maintenance) | 0.25/0.5 mg pen (red label) |
| 9-12 | 1.0 mg | Yellow | 1.0 mg (optional) | 1.0 mg pen (blue label) |
| 13-16 | 1.7 mg | Teal/cyan | N/A | N/A |
| 17+ | 2.4 mg (maintenance) | Dark blue | 2.0 mg (optional) | 2.0 mg pen (new pen) |
What are the Wegovy dose escalation steps?
The Wegovy dose escalation follows five 4-week steps: Step 1 is 0.25 mg weekly for weeks 1 through 4, Step 2 is 0.5 mg weekly for weeks 5 through 8, Step 3 is 1.0 mg weekly for weeks 9 through 12, Step 4 is 1.7 mg weekly for weeks 13 through 16, and Step 5 is the maintenance dose of 2.4 mg weekly starting at week 17 and continuing indefinitely. Each step requires a different pre-filled pen device. The total titration takes 16 weeks (approximately 4 months) to complete.
What if I cannot tolerate a dose increase?
If a dose increase causes intolerable side effects (severe nausea, vomiting, or diarrhea that persists beyond 3 to 5 days), the recommended approach is to remain at the current dose for an additional 4 weeks before attempting the increase again. This extended titration strategy allows the body more time to adapt. If the dose remains intolerable after a second attempt, your physician may decide that the previous dose is your maximum tolerated dose and maintain you there rather than escalating further. Many patients achieve meaningful weight loss at sub-maximal doses.
Can I skip dose levels to get to the maintenance dose faster?
No, skipping dose levels is strongly discouraged and contrary to the FDA-approved prescribing information. The gradual titration is not arbitrary; it allows the gastrointestinal tract to adapt to GLP-1 receptor stimulation. Patients who skip levels experience significantly higher rates of nausea (70 to 80 percent versus 40 to 50 percent with standard titration), vomiting, and sometimes severe enough symptoms to require emergency department visits. The 16-week titration should be viewed as an investment in long-term tolerability.
What happens if I miss my weekly injection?
If you miss a dose and it has been less than 5 days since the missed injection day, take the injection as soon as possible and resume your regular weekly schedule. If it has been 5 or more days, skip the missed dose and take your next dose on the regularly scheduled day. Do not take two injections in one week to make up for a missed dose. If you miss 2 or more consecutive weekly doses, contact your prescriber, as you may need to restart at a lower dose depending on your current titration phase and the duration of the gap.
How do the Ozempic and Wegovy dose schedules differ?
Ozempic for type 2 diabetes starts at 0.25 mg for 4 weeks, then increases to 0.5 mg as the initial maintenance dose. Further increases to 1.0 mg and then 2.0 mg are optional and based on glycemic response, not a fixed schedule. Wegovy for weight management follows a mandatory 5-step escalation to 2.4 mg over 16 weeks. The key differences are that Ozempic's escalation is flexible and physician-directed while Wegovy's is protocol-driven, and Wegovy reaches a higher maximum dose (2.4 mg versus 2.0 mg) because the weight management indication requires higher GLP-1 receptor occupancy.
Why does each Wegovy dose use a different pen?
Each Wegovy dose level uses a different pre-filled, single-use pen device because the concentration of semaglutide in solution varies by dose, and fixed-dose pens eliminate the risk of dose selection errors. Unlike Ozempic, which uses a multi-dose pen with a dial that the patient adjusts, Wegovy pens deliver exactly one dose per injection with no user adjustment. This design improves dosing accuracy and safety but means patients need a new prescription and pharmacy order when transitioning between dose levels. Each pen has a distinct label color to prevent mix-ups.
How should I store my semaglutide pens?
Unused semaglutide pens should be stored in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Once a pen is in use (for Ozempic multi-dose pens), it can be stored at room temperature below 86 degrees Fahrenheit (30 degrees Celsius) for up to 56 days. Wegovy single-use pens should be refrigerated until use. Never freeze semaglutide, and do not use a pen that has been frozen. Protect pens from direct sunlight and heat. When traveling, use an insulated medication travel case with a cold pack.
Pro Tip
Set a recurring weekly alarm on your phone for your injection day and time. Consistency in timing helps maintain steady drug levels and makes it easier to remember whether you have taken your weekly dose. If you experience nausea, try injecting in the evening so you can sleep through the peak nausea period, and eat smaller, blander meals for the 24 hours following injection until your body adjusts to each new dose level.
Did you know?
Semaglutide was engineered to have a half-life of approximately 7 days by attaching a fatty acid chain (C18 fatty di-acid) to the GLP-1 molecule, which causes it to bind to albumin in the blood and be released slowly. Natural GLP-1 produced by the gut has a half-life of only 2 to 3 minutes because it is rapidly degraded by the enzyme DPP-4. This 3,000-fold extension of the half-life is what makes once-weekly dosing possible.